Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature
Abstract Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with c...
Saved in:
| Main Authors: | Guangjian Yang, Linyan Tian, Yan Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-01749-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Amivantamab versus standard therapies among patients with advanced non-small cell lung cancer and epidermal growth factor receptor exon 20 insertion mutations after platinum-based therapy in China
by: Lan Shen, et al.
Published: (2025-08-01) -
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01) -
Interpretation of Key Points in 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer
by: Xuanhong JIN, et al.
Published: (2025-06-01) -
Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertions
by: Kung-Yang Wang, et al.
Published: (2025-03-01) -
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)